Cardiometabolic multimorbidity and associated clinical, lifestyle and genetic factors among Ghanaian patients

BACKGROUND: Cardiometabolic multimorbidity (coexistence of hypertension, type 2 diabetes, metabolic syndrome and chronic kidney disease) is rising in sub‑Saharan Africa (SSA), but data integrating clinical, lifestyle and genetic determinants in Ghana are limited. This study aimed to characterise the burden of cardiometabolic multimorbidity among Ghanaian clinic attendees and evaluate the associations of clinical, lifestyle, and candidate genetic variants with hypertension, diabetes, metabolic syndrome, and CKD. METHODS: This cross-sectional study assessed 203 adults attending specialised clinics at a tertiary hospital in Cape Coast, Ghana, between 17 May 2023 and 30 April 2024. Data were collected on participants' sociodemographic and clinicodemographic characteristics, in addition to lifestyle information obtained through structured questionnaires. Selected candidate variants (TCF7L2 rs7903146, AGT rs699, ACE rs4343, LEPR rs1137101, ADRB3 rs4994, KCNJ11 rs5219, PPARG rs1801282, APOL1 risk variants) were genotyped. Multivariable logistic regression models were used to evaluate the determinants of blood pressure, elevated glucose levels, metabolic syndrome, and CKD. Receiver operating characteristic analysis compared the predictive performance of clinical/lifestyle, genetic, and combined models. RESULTS: Over 80% of participants had ≥ 2 cardiometabolic conditions; > 80% were overweight/obese, and >2/3 met the metabolic syndrome criteria. Despite high treatment rates, uncontrolled BP and hyperglycaemia were common. Obesity was the strongest independent predictor of CKD (aORs:7-8 for Obese I/II). The use of glucose-lowering medication was associated with better glycaemic control (OR: 7.16, 95% CI: 3.31-15.47, p < 0.001), and antihypertensive treatment was correlated with lower odds of uncontrolled BP (aOR: 0.25, 95% CI: 0.07-0.90, p = 0.033). Among the genetic markers, the TCF7L2 rs7903146 CT genotype was associated with higher odds of hypertension (adjusted odds ratio [aOR]: 2.15, 95% CI: 1.06-4.37, p = 0.034). Most other variants, including APOL1, showed no consistent associations. Combined clinical, lifestyle, and genetic models had the highest discrimination (AUCs: 0.83-0.89), followed by clinical/lifestyle models (AUCs: 0.76-0.83), while genetic-only models performed poorly (AUCs: 0.63-0.67). CONCLUSIONS: In this Ghanaian cohort, cardiometabolic multimorbidity is highly prevalent and appears to be driven predominantly by modifiable risk factors, particularly obesity. Immediate gains are likely from integrated risk factor management; however, genetic findings are exploratory and require replication in larger, community-based cohorts.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-17
DOI
https://doi.org/10.1371/journal.pone.0362848
Primary Topic
Chronic Disease Management Strategies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cardiometabolic multimorbidity and associated clinical, lifestyle and genetic factors among Ghanaian patients

Cyril E. K. Gavor-Kwashi, Richard Kojo Yankah, Ansumana Sandy Bockarie, Samuel Badu Nyarko et al.
1 links
PLoS ONE
Chronic Disease Management Strategies
article

Cardiometabolic multimorbidity and associated clinical, lifestyle and genetic factors among Ghanaian patients

Cyril E. K. Gavor-Kwashi, Richard Kojo Yankah, Ansumana Sandy Bockarie, Samuel Badu Nyarko, Nicholas Ekow Thomford, Dee Blackhurst, Richmond Owusu Ateko, Foster Kyei, Ebenezer Allotey Pappoe, Oksana Ryabinina, Joel Adu Twum, John Anyimadu, Vanessa Naa Torshie Mensah, Ebenezer Aniakwa-Bonsu, Naa Aku Addo
article en

Abstract

BACKGROUND: Cardiometabolic multimorbidity (coexistence of hypertension, type 2 diabetes, metabolic syndrome and chronic kidney disease) is rising in sub‑Saharan Africa (SSA), but data integrating clinical, lifestyle and genetic determinants in Ghana are limited. This study aimed to characterise the burden of cardiometabolic multimorbidity among Ghanaian clinic attendees and evaluate the associations of clinical, lifestyle, and candidate genetic variants with hypertension, diabetes, metabolic syndrome, and CKD. METHODS: This cross-sectional study assessed 203 adults attending specialised clinics at a tertiary hospital in Cape Coast, Ghana, between 17 May 2023 and 30 April 2024. Data were collected on participants' sociodemographic and clinicodemographic characteristics, in addition to lifestyle information obtained through structured questionnaires. Selected candidate variants (TCF7L2 rs7903146, AGT rs699, ACE rs4343, LEPR rs1137101, ADRB3 rs4994, KCNJ11 rs5219, PPARG rs1801282, APOL1 risk variants) were genotyped. Multivariable logistic regression models were used to evaluate the determinants of blood pressure, elevated glucose levels, metabolic syndrome, and CKD. Receiver operating characteristic analysis compared the predictive performance of clinical/lifestyle, genetic, and combined models. RESULTS: Over 80% of participants had ≥ 2 cardiometabolic conditions; > 80% were overweight/obese, and >2/3 met the metabolic syndrome criteria. Despite high treatment rates, uncontrolled BP and hyperglycaemia were common. Obesity was the strongest independent predictor of CKD (aORs:7-8 for Obese I/II). The use of glucose-lowering medication was associated with better glycaemic control (OR: 7.16, 95% CI: 3.31-15.47, p < 0.001), and antihypertensive treatment was correlated with lower odds of uncontrolled BP (aOR: 0.25, 95% CI: 0.07-0.90, p = 0.033). Among the genetic markers, the TCF7L2 rs7903146 CT genotype was associated with higher odds of hypertension (adjusted odds ratio [aOR]: 2.15, 95% CI: 1.06-4.37, p = 0.034). Most other variants, including APOL1, showed no consistent associations. Combined clinical, lifestyle, and genetic models had the highest discrimination (AUCs: 0.83-0.89), followed by clinical/lifestyle models (AUCs: 0.76-0.83), while genetic-only models performed poorly (AUCs: 0.63-0.67). CONCLUSIONS: In this Ghanaian cohort, cardiometabolic multimorbidity is highly prevalent and appears to be driven predominantly by modifiable risk factors, particularly obesity. Immediate gains are likely from integrated risk factor management; however, genetic findings are exploratory and require replication in larger, community-based cohorts.

PLoS ONEVol. 21(11)
University of Cape Coast (GH), University of Ghana (GH), University of Cape Town (ZA), University of Ghana Medical Centre (GH), Cape Coast Teaching Hospital (GH)
Good health and well-being
Chronic Disease Management Strategies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon